Skip to main content
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences 2/2012

01.03.2012 | Original article

A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer

verfasst von: Hiroyuki Shinchi, Kosei Maemura, Yuko Mataki, Hiroshi Kurahara, Masahiko Sakoda, Shinichi Ueno, Yoshiyuki Hiraki, Masayuki Nakajo, Shoji Natsugoe, Sonshin Takao

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background/purpose

S-1 is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. In a previous phase I trial, we evaluated the safety of S-1 combined with radiotherapy to determine the maximum tolerated dose and dose-limiting toxicity in patients with unresectable pancreatic cancer. The recommended dose of S-1 for phase II trials of chemoradiotherapy was determined as 80 mg/m2/day given on days 1–21 of a 28-day cycle. This phase II study was conducted to further evaluate the efficacy and toxicity of radiotherapy combined with S-1 (UMIN000004794).

Methods

Eligible patients had locally advanced and unresectable pancreatic cancer without distant metastases, an Eastern Cooperative Oncology Group performance status of 0–1, adequate organ and marrow functions, and no prior anticancer therapy. Patients initially received 4 weeks of chemoradiotherapy. S-1 was given orally at a dose of 80 mg/m2/day twice daily on days 1–21. Radiotherapy was delivered in fractions of 1.25 Gy twice daily, 5 days per week for 4 weeks (total dose: 50 Gy in 40 fractions). One month after the completion of chemoradiotherapy, S-1 was administered for 14 days followed by a 14-day rest period. This cycle was repeated as maintenance therapy until disease progression or unacceptable toxicity.

Results

Fifty patients were enrolled in this phase II study. Median follow-up was 14.6 months (range 5.4–58.9 months). Forty-three patients (86%) completed the scheduled course of chemoradiotherapy. There was no treatment-related death or grade 4 toxicity. The major toxic effects were leukopenia and nausea. The objective tumor response according to the Response Evaluation Criteria in Solid Tumours criteria was partial response in 15 patients (30%) (95% confidence interval (CI), 18–45%), stable disease in 23 (46%), and progressive disease in 12 (24%). Median progression-free survival and median overall survival were 6.7 months (95% CI, 4.7–11.2 months) and 14.3 months (95% CI, 10.8–20.8 months), respectively. Survival rates at 1 and 2 years were 62 and 27%, respectively.

Conclusions

Combination therapy with S-1 and radiation in patients with locally advanced and unresectable pancreatic cancer is considered a promising, well-tolerated regimen that can be recommended as an effective treatment for locally advanced pancreatic cancer.
Literatur
1.
Zurück zum Zitat Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, et al. The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg. 2009;16:485–92.PubMedCrossRef Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, et al. The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg. 2009;16:485–92.PubMedCrossRef
2.
Zurück zum Zitat Ueno H, Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2008;15:468–72.PubMedCrossRef Ueno H, Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2008;15:468–72.PubMedCrossRef
3.
Zurück zum Zitat Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer. 1981;48:1705–10.CrossRef Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer. 1981;48:1705–10.CrossRef
4.
Zurück zum Zitat Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–5.CrossRef Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–5.CrossRef
5.
Zurück zum Zitat Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed
6.
Zurück zum Zitat Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208–12.PubMed Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208–12.PubMed
7.
Zurück zum Zitat McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202–8.PubMed McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202–8.PubMed
8.
Zurück zum Zitat Fung MC, Sakata T. What’s new in pancreatic cancer treatment? J Hepatobiliary Pancreat Surg. 2002;9:61–75.PubMedCrossRef Fung MC, Sakata T. What’s new in pancreatic cancer treatment? J Hepatobiliary Pancreat Surg. 2002;9:61–75.PubMedCrossRef
9.
Zurück zum Zitat Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91:673–7.PubMed Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91:673–7.PubMed
10.
Zurück zum Zitat Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer—a multi-center randomized phase II study. Br J Cancer. 2009;101:1853–9.PubMedCrossRef Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer—a multi-center randomized phase II study. Br J Cancer. 2009;101:1853–9.PubMedCrossRef
11.
Zurück zum Zitat Richter J, Saif MW. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? J Pancreas. 2010;11:139–43. Richter J, Saif MW. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? J Pancreas. 2010;11:139–43.
12.
Zurück zum Zitat Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.PubMedCrossRef Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.PubMedCrossRef
13.
Zurück zum Zitat Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004–9.PubMed Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004–9.PubMed
14.
Zurück zum Zitat Koizumi W, Kurihara M, Nakano S, Hasegawa K, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.PubMedCrossRef Koizumi W, Kurihara M, Nakano S, Hasegawa K, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.PubMedCrossRef
15.
Zurück zum Zitat Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, S-1 Cooperative Colorectal Carcinoma Study Group, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer. 2000;83:141–5.PubMedCrossRef Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, S-1 Cooperative Colorectal Carcinoma Study Group, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer. 2000;83:141–5.PubMedCrossRef
16.
Zurück zum Zitat Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171–8.PubMedCrossRef Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171–8.PubMedCrossRef
17.
Zurück zum Zitat Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:615–21.PubMedCrossRef Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:615–21.PubMedCrossRef
18.
Zurück zum Zitat Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13:693–8.PubMed Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13:693–8.PubMed
19.
Zurück zum Zitat Harada K, Kawaguchi S, Supriatno Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004;40:713–9.PubMedCrossRef Harada K, Kawaguchi S, Supriatno Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004;40:713–9.PubMedCrossRef
20.
Zurück zum Zitat Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Akihiko N, et al. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiation Oncology Biol Phys. 2007;67:219–24.CrossRef Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Akihiko N, et al. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiation Oncology Biol Phys. 2007;67:219–24.CrossRef
21.
Zurück zum Zitat Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse F, et al. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer. 2007;96:1650–5.PubMedCrossRef Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse F, et al. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer. 2007;96:1650–5.PubMedCrossRef
22.
Zurück zum Zitat Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:535–41.PubMedCrossRef Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:535–41.PubMedCrossRef
23.
Zurück zum Zitat Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010, Jun 2. (Epub ahead of print). Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010, Jun 2. (Epub ahead of print).
24.
Zurück zum Zitat Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer. 2007;96:1353–7.PubMed Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer. 2007;96:1353–7.PubMed
25.
Zurück zum Zitat Maemura K, Shinchi H, Noma H, Mataki Y, Kurahara H, Maeda S, et al. Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res. 2008;28:2369–72.PubMed Maemura K, Shinchi H, Noma H, Mataki Y, Kurahara H, Maeda S, et al. Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res. 2008;28:2369–72.PubMed
26.
Zurück zum Zitat Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004;15:85–106.PubMedCrossRef Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004;15:85–106.PubMedCrossRef
27.
Zurück zum Zitat Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006;94:1575–9.PubMed Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006;94:1575–9.PubMed
28.
Zurück zum Zitat Okusaka T, Ito Y, Furuse J, Yamada S, Ishii H, Shibuya K, et al. Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan. Int J Clin Oncol. 2008;13:127–31.PubMedCrossRef Okusaka T, Ito Y, Furuse J, Yamada S, Ishii H, Shibuya K, et al. Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan. Int J Clin Oncol. 2008;13:127–31.PubMedCrossRef
29.
Zurück zum Zitat Wendt CD, Peters LJ, Ang KK, Morrison WH, Maor MH, Goepfert H, et al. Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx. Int J Radiat Oncol Biol Phys. 1989;17:1057–62.PubMedCrossRef Wendt CD, Peters LJ, Ang KK, Morrison WH, Maor MH, Goepfert H, et al. Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx. Int J Radiat Oncol Biol Phys. 1989;17:1057–62.PubMedCrossRef
Metadaten
Titel
A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer
verfasst von
Hiroyuki Shinchi
Kosei Maemura
Yuko Mataki
Hiroshi Kurahara
Masahiko Sakoda
Shinichi Ueno
Yoshiyuki Hiraki
Masayuki Nakajo
Shoji Natsugoe
Sonshin Takao
Publikationsdatum
01.03.2012
Verlag
Springer Japan
Erschienen in
Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 2/2012
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-011-0400-y

Weitere Artikel der Ausgabe 2/2012

Journal of Hepato-Biliary-Pancreatic Sciences 2/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.